Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase…
By E. Pujade-Lauraine, Jonathan A. Ledermann, F. Selle, V. Gebski, R. Penson, A. Oza, J. Korach, T. Huzarski, A. Poveda, S. Pignata and 10 more. The Lancet Oncology, 2017
1,515 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/3c8f38d45e7b56f4baca6df426bc91d73646ff41
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Reproductive Medicine
Citations in the corpus
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, methodology): “For SOLO2 [36], TFST analysis was preplanned and showed an additional advantage of 7.”
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2019, neutral): “Anemia† 25 (27) 10 (11) 10 (17) 2 (3) 11 (−3 to 24) 8 (−2 to 17)”
- A decade of clinical development of PARP inhibitors in perspective (2019, background): “5 m for olaparib and placebo, respectively) [24].”
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019, methodology): “Olaparib maintenance treatment following platinum-based chemotherapy in patients with a BRCA mutation led to an improvement in PFS in study 19(35) and in the SOLO2 trial.(36) In study 19, patients without a BRCA mutation also derived a significant benefit in PFS.”